Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Current Investments: 2022-2025

Historic Cash & Current Investments for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $451.6 million.

  • Day One Biopharmaceuticals' Cash & Current Investments fell 19.13% to $451.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 19.00%. This contributed to the annual value of $531.7 million for FY2024, which is 45.14% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Cash & Current Investments is $451.6 million, which was down 0.34% from $453.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Cash & Current Investments' 5-year high stood at $558.4 million during Q3 2024, with a 5-year trough of $262.7 million in Q1 2022.
  • For the 3-year period, Day One Biopharmaceuticals' Cash & Current Investments averaged around $425.5 million, with its median value being $442.9 million (2023).
  • Data for Day One Biopharmaceuticals' Cash & Current Investments shows a peak YoY increase of 48.77% (in 2025) and a maximum YoY decrease of 19.13% (in 2025) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Cash & Current Investments (Quarterly) stood at $342.3 million in 2022, then climbed by 7.03% to $366.3 million in 2023, then soared by 45.14% to $531.7 million in 2024, then declined by 19.13% to $451.6 million in 2025.
  • Its last three reported values are $451.6 million in Q3 2025, $453.1 million for Q2 2025, and $473.0 million during Q1 2025.